Find information on thousands of medical conditions and prescription drugs.

Short bowel syndrome

Short bowel syndrome is a malabsorption disorder caused by either the surgical removal of the small intestine or the loss of its absorptive function due to diseases. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
Sabinas brittle hair...
Saccharopinuria
Sacral agenesis
Saethre-Chotzen syndrome
Salla disease
Salmonellosis
Sandhoff disease
Sanfilippo syndrome
Sarcoidosis
Say Meyer syndrome
Scabies
Scabiophobia
Scarlet fever
Schamberg disease...
Schistosomiasis
Schizencephaly
Schizophrenia
Schmitt Gillenwater Kelly...
Sciatica
Scimitar syndrome
Sciophobia
Scleroderma
Scrapie
Scurvy
Selachophobia
Selective mutism
Seminoma
Sensorineural hearing loss
Seplophobia
Sepsis
Septo-optic dysplasia
Serum sickness
Severe acute respiratory...
Severe combined...
Sezary syndrome
Sheehan syndrome
Shigellosis
Shingles
Shock
Short bowel syndrome
Short QT syndrome
Shprintzen syndrome
Shulman-Upshaw syndrome
Shwachman syndrome
Shwachman-Diamond syndrome
Shy-Drager syndrome
Sialidosis
Sickle-cell disease
Sickle-cell disease
Sickle-cell disease
Siderosis
Silicosis
Silver-Russell dwarfism
Sipple syndrome
Sirenomelia
Sjogren's syndrome
Sly syndrome
Smallpox
Smith-Magenis Syndrome
Sociophobia
Soft tissue sarcoma
Somniphobia
Sotos syndrome
Spasmodic dysphonia
Spasmodic torticollis
Spherocytosis
Sphingolipidosis
Spinal cord injury
Spinal muscular atrophy
Spinal shock
Spinal stenosis
Spinocerebellar ataxia
Splenic-flexure syndrome
Splenomegaly
Spondylitis
Spondyloepiphyseal...
Spondylometaphyseal...
Sporotrichosis
Squamous cell carcinoma
St. Anthony's fire
Stein-Leventhal syndrome
Stevens-Johnson syndrome
Stickler syndrome
Stiff man syndrome
Still's disease
Stomach cancer
Stomatitis
Strabismus
Strep throat
Strongyloidiasis
Strumpell-lorrain disease
Sturge-Weber syndrome
Subacute sclerosing...
Sudden infant death syndrome
Sugarman syndrome
Sweet syndrome
Swimmer's ear
Swyer syndrome
Sydenham's chorea
Syncope
Syndactyly
Syndrome X
Synovial osteochondromatosis
Synovial sarcoma
Synovitis
Syphilis
Syringomas
Syringomyelia
Systemic carnitine...
Systemic lupus erythematosus
Systemic mastocytosis
Systemic sclerosis
T
U
V
W
X
Y
Z
Medicines

In healthy adults, the small intestine has an average length of approximately 6 meters (20 feet). Short bowel syndrome usually appears when there is less than 1.8 meters (6 feet) of the small intestine left to absorb sufficient nutrients.

Symptoms

The symptoms of short bowel syndrome include:

  • Abdominal pain
  • Diarrhoea
  • Steatorrhoea or particularly foul-odored faeces
  • Oily or sticky stool
  • Fluid retention
  • Weight loss and malnutrition
  • Fatigue

Patients with short bowel syndrome may have complications caused by malabsorption of vitamins and minerals, such as deficiencies in vitamins A, E, D, and B12, calcium, magnesium, iron, folic acid, and zinc. These may appear as anaemia, scaling of the skin or hyperkeratosis, easy bruising, muscle spasms, and bone pain.

Causes

Short bowel syndrome in adults is usually caused by:

  • Crohn's disease, an inflammatory disorder of the digestive tract
  • Volvulus, a spontaneous twisting of the small intestine that cuts off the blood supply and leads to necrosis or tissue death.
  • Cancer of the small intestine
  • Injury or trauma to the small intestine
  • Bowel bypass surgery to treat obesity, now a rarely performed surgical procedure to remove a portion of the small intestine.
  • Surgery to remove diseases or damaged portion of the small intestine.

This condition can also develop in premature infants who has necrotizing enterocolitis, a serious disease where dead tissues in the lining of the small intestine needs to be surgically removed.

Treatments

Symptoms of short bowel syndrome are usually addressed by prescription medicine. These include:

  • Anti-diarrheal medicine
  • Vitamin and mineral supplements
  • H2 blocker and proton pump inhibitors to reduce stomach acid
  • Lactase supplement
  • Surgery, including intestinal lengthening, tapering, and organ transplant.

Newborn infants may require parenteral nutrition (or nutrition administered via intravenous line).

Intestinal adaptation

Short bowel syndrome caused by the surgical removal of a portion of the bowel may be a temporary condition, due to the adaptive property of the small intestine.

In a process called intestinal adaptation, physiological changes to the remaining portion of the small intestine occur to increase its absorptive capacity. These changes include:

  • Enlargement and lengthening of the villi found in the lining
  • Increase in the diameter of the small intestine
  • Slow down in peristalsis or movement of food through the small intestine

Read more at Wikipedia.org


[List your site here Free!]


Tegaserod in patients with irritable bowel syndrome
From American Family Physician, 12/1/04 by Michael Schooff

This clinical content conforms to AAFP criteria for evidence-based continuing medical education (EB CME). EB CME is clinical content presented with practice recommendations supported by evidence that has been systematically reviewed by an AAFP-approved source. The practice recommendations in this activity are available online at http://www.cochrane.org/cochrane/revabstr/AB003960.htm.

The Cochrane Abstract below is a summary of a review from the Cochrane Library. It is accompanied by an interpretation that will help clinicians put evidence into practice. Michael Schooff, M.D., and Casey Stelter, M.D., present a clinical scenario and question based on the Cochrane Abstract, along with the evidence-based answer and a full critique of the abstract.

Clinical Scenario

A 35-year-old woman presents with recurrent episodes of abdominal pain, constipation, and a sense of incomplete emptying after defecation. She has a history of irritable bowel syndrome (IBS).

Clinical Question

In patients with IBS, is tegaserod an appropriate therapy for treatment of abdominal pain and general dissatisfaction with bowel habits?

Evidence-Based Answer

Tegaserod offers modest improvement in global gastrointestinal (GI) symptoms in women with constipation-predominant IBS, without having significant effect on symptoms of abdominal pain and discomfort.

Practice Pointers

IBS is a chronic, relapsing condition encompassing a wide variety of GI symptoms, including abdominal pain and altered bowel habits. The condition affects 10 to 15 per-cent of the North American population and is twice as common in women as in men. (2) The etiology is unknown, although motility disorders, visceral hypersensitivity, and sensitization of the central nervous system have been implicated. IBS is a clinical diagnosis of exclusion, and traditional treatments, such as bulking agents, anticholinergics, antispasmodics, antidiarrheals, and antidepressants, have targeted individual symptoms. Tegaserod, which stimulates smooth muscle within the GI tract and increases peristalsis and gut transit time, offers a new treatment option for the global symptoms of IBS.

Tegaserod in dosages of 12 mg daily has shown statistical significance in two studies, and a nonsignificant but beneficial trend in two additional randomized controlled studies, in the reduction of global GI symptoms. These self-reported subjective assessments asked patients to compare their GI symptoms before entering the trial with symptoms after initiating therapy. Patients in both treatment groups reported complete or considerable relief in GI symptoms.

Abdominal pain symptoms did not appear to be altered significantly, although beneficial trends were noted in some patients in both treatment groups. Patient satisfaction with bowel habits suggests that the lower dosage may be more efficacious, although a similar trend in patient satisfaction was noted in the higher dosage group.

Stool frequency and the number of days without bowel movements improved in patients in the 12-mg group. In one study, subjective scores of bloating, straining, and stool consistency decreased and stool frequency increased in the higher dosage group. However, these results were not consistent across all studies.

Tegaserod was well tolerated by most patients. The most common side effect was diarrhea, which was experienced significantly more often by patients in the higher dosage group (NNH, 20). Headache, abdominal pain, and nausea were experienced with increased frequency in this group as well, but this trend did not reach statistical significance. Cardiac effects were not apparent with this agent as they are with other partial 5-H[T.sub.4] receptor agonist GI-motility agents such as cisapride. Three studies investigated the potential effect of QTc interval prolongation but did not identify an increase in frequency of ECG abnormalities between the high-dosage, low-dosage, and placebo groups.

Few data about tegaserod's efficacy in men and its impact on quality of life exist. Longer-term studies are needed to determine the duration of treatment and the safety of this agent with prolonged use. Tegaserod appears to be an option for short-term relief of global GI symptoms in women with constipation-predominant IBS, but it does not affect their abdominal pain and discomfort.

REFERENCES

(1.) Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004;(1):CD003960.

(2.) Holten KB. Irritable bowel syndrome: minimize testing, let symptoms guide treatment. J Fam Pract 2003;52:942-50.

RELATED ARTICLE: Cochrane abstract.

Background. IBS is a complex disorder that encompasses a wide profile of symptoms. Current drug treatments for IBS are of limited value, and many treatments target specific symptoms. Tegaserod, a 5-H[T.sub.4] receptor partial agonist, has a novel mechanism of action in the treatment of IBS.

Objectives. The objective of this review (1) was to evaluate the efficacy and tolerability of tegaserod in the treatment of IBS in patients 12 years of age and older.

Search Strategy. The authors searched MEDLINE (1966 to November 2002) and EMBASE (1980 to November 2002) using the key words "tegaserod," "HTF 919," "irritable bowel," and "colonic diseases, functional." The Cochrane Central Register of Controlled Trials, the Inflammatory Bowel Disease Review Group Specialized Trials Register, and Science Citation Index also were searched. Proceedings from the British Society of Gastroenterology Annual Meeting, and Digestive Disease Week (1998 to 2002) were searched by hand. Reference lists from relevant articles were reviewed. The manufacturer of tegaserod was contacted.

Selection Criteria. Randomized or quasi-randomized controlled trials that focused on clinical end points and compared tegaserod with placebo, no treatment, or any other intervention (pharmacologic or nonpharmacologic) in patients 12 years and older who had been diagnosed with IBS were considered for review.

Data Collection and Analysis. Study inclusion and exclusion, data extraction, and quality assessment were performed independently by two reviewers. Meta-analysis was performed when study populations, designs, outcomes, and statistical reporting allowed the valid combination of data. Eight short-term, placebo-controlled studies fulfilled the inclusion criteria. These studies were conducted pre-dominantly in women. Seven studies evaluated the efficacy of tegaserod on global GI symptoms in patients with constipation-predominant IBS. One small study evaluated safety in patients with diarrhea-predominant IBS.

Primary Results. Compared with patients who received placebo, the relative risk (RR) of responding in terms of global relief of GI symptoms was significantly higher in patients who received tegaserod in dosages of 12 mg per day (RR, 1.19; 95 percent confidence interval [CI], 1.09 to 1.29) and 4 mg per day (RR, 1.15; 95 percent CI, 1.02 to 1.31), with numbers needed to treat (NNT) of 14 and 20, respectively. When patients who received tegaserod at any dosage (n = 4,040) were compared with patients who received placebo, the RR of responding was 1.17 (95 percent CI, 1.08 to 1.27), with an NNT of 17. Although the pooled results indicate a statistically significant benefit with tegaserod, the a priori minimal clinically important differences that were set in two of the four pooled studies were not reached. Tegaserod did not significantly improve patients' individual symptoms of abdominal pain and discomfort, although a statistically significant improvement in bowel habits was noted in patients in the lower dosage group. There was a nonsignificant trend in favor of the 12-mg dosage.

When GI symptoms were assessed separately, symptoms indicative of GI motility, such as number of bowel movements and days without bowel movements, generally were improved in patients who received tegaserod, although the proportion of patients experiencing diarrhea was significantly higher in the 12-mg group than in the placebo group (RR, 2.75; 95 percent CI, 1.90 to 3.97), with a number needed to harm (NNH) of 20. The effects of tegaserod on GI symptoms such as bloating, stool consistency, and straining were not consistent across the studies.

Reviewers' Conclusions. Tegaserod appears to improve the overall symptomatology of IBS, but there are few data on its effect on quality of life. More information is needed about its efficacy in men. It also would be of interest to know whether treatment with tegaserod sensitivity or psychopathology, which are considered important in the pathophysiology of this condition.

These summaries have been derived from Cochrane reviews published in the Cochrane Database of Systematic Reviews in the Cochrane Library. Their content has, as far as possible, been checked with the authors of the original reviews, but the summaries should not be regarded as an official product of the Cochrane Collaboration; minor editing changes have been made to the text (www.cochrane.org).

The Authors

MICHAEL SCHOOFF, M.D., is associate director of the Clarkson Family Medicine Residency Program in Omaha. He received his medical degree from the Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, Md., and completed a family practice residency at Womack Army Medical Center, Fort Bragg, N.C. CASEY STELTER, M.D., is a third-year family medicine resident at the Clarkson Family Medicine Residency Program in Omaha. He received his medical degree from the University of Utah School of Medicine, Salt Lake City.

Address correspondence to Michael Schooff, M.D., Clarkson Family Medicine, 4200 Douglas St., Omaha, NE 68131 (e-mail: mschooff@nebraskamed.com). Reprints are not available from the authors.

COPYRIGHT 2004 American Academy of Family Physicians
COPYRIGHT 2004 Gale Group

Return to Short bowel syndrome
Home Contact Resources Exchange Links ebay